Role of RUNX1 in hematological malignancies

357Citations
Citations of this article
463Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

RUNX1 is a member of the core-binding factor family of transcription factors and is indispensable for the establishment of definitive hematopoiesis in vertebrates. RUNX1 is one of the most frequently mutated genes in a variety of hematological malignancies. Germ line mutations in RUNX1 cause familial platelet disorder with associated myeloid malignancies. Somatic mutations and chromosomal rearrangements involving RUNX1 are frequently observed in myelodysplastic syndrome and leukemias of myeloid and lymphoid lineages, that is, acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelomonocytic leukemia. More recent studies suggest that the wild-type RUNX1 is required for growth and survival of certain types of leukemia cells. The purpose of this review is to discuss the current status of our understanding about the role of RUNX1 in hematological malignancies.

Cite

CITATION STYLE

APA

Sood, R., Kamikubo, Y., & Liu, P. (2017, April 13). Role of RUNX1 in hematological malignancies. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2016-10-687830

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free